(MENAFN- GlobeNewsWire - Nasdaq) The gene editing technologies market is driven by technological advancements enhancing precision, expanding applications in personalized medicine, and rising genetic disorder prevalence. Despite off-target effect concerns, trends toward *in vivo* therapies simplify treatments and boost growth, supported by substantial government research funding.

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Technologies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets's offering.
The Global Gene Editing Technologies Market, valued at USD 5.78 Billion in 2024, is projected to experience a CAGR of 10.30% to reach USD 10.41 Billion by 2030.

Gene editing technologies encompass methods enabling highly specific changes to an organism's DNA, facilitating the precise addition, removal, or alteration of genetic material at targeted genomic locations. The market's growth is primarily driven by continuous technological advancements, the expanding utility of gene editing across diverse applications, and increasing demand for personalized medicine. Furthermore, the rising global prevalence of genetic and chronic disorders, coupled with substantial government funding for related research, significantly contributes to market expansion.

The global gene editing technologies market is profoundly influenced by continuous advancements in the precision and scope of gene editing tools. Innovations consistently emerge, enhancing the safety and accuracy of genetic modifications. For example, according to Massachusetts Institute of Technology, October 10, 2025, "MIT's new precision gene editing tool could transform medicine," a new system makes 60 times fewer mistakes than previous iterations, significantly improving targeting capabilities.

These technological refinements directly enable the expanding therapeutic and research applications of gene editing. As tools become more reliable, the range of treatable diseases broadens, and the feasibility of complex genetic interventions increases. This expansion is evident in the burgeoning clinical pipeline.
Key Market Challenges
Persistent concerns regarding off-target effects present a significant impediment to the growth of the Global Gene Editing Technologies Market. These effects, where unintended genetic alterations occur at locations other than the targeted site, introduce substantial safety risks for patients. Such unpredictable outcomes necessitate extensive preclinical and clinical scrutiny, prolonging development timelines and increasing research expenditures. The inherent unpredictability associated with off-target editing directly influences regulatory bodies' cautious approach to product approvals, leading to more stringent testing requirements and extended observational periods for gene-edited therapies.
The impact of these safety concerns is reflected in development setbacks.
Key Market Trends
Accelerated Development of In Vivo Gene Therapies is a significant trend, representing a critical shift towards direct administration of genetic material into the body, thereby bypassing complex *ex vivo* cell manipulation. This approach offers broader therapeutic applicability, simpler administration, and reduced manufacturing complexities, particularly for systemic diseases or difficult-to-access tissues. According to Towards Healthcare, the *in vivo* gene therapy segment constituted approximately 55% of the gene therapy clinical trials market in 2024, indicating its substantial and growing prevalence. This modality is accelerating clinical development pathways.

Key Attributes:

Report Attribute	Details
No. of Pages	180
Forecast Period	2024 - 2030
Estimated Market Value (USD) in 2024	$5.78 Billion
Forecasted Market Value (USD) by 2030	$10.41 Billion
Compound Annual Growth Rate	10.3%
Regions Covered	Global

Report Scope:

Key Market Players Profiled:

• Addgene Inc.
• BRAIN Biotech AG
• Cellectis S.A.
• Creative Biolabs, Inc.
• CRISPR Therapeutics AG
• BioRad Laboratories, Inc.
• DNA Script SAS
• GeneCopoeia, Inc.
• Merck KGaA
• PerkinElmer Inc.

By Offerings:

• Gene Editing Products
• Gene Editing Services

By Technology:

• CRISPR Gene Editing Technology
• Non-CRISPR Gene Editing Technology

By Application:

• Agricultural
• Biomedical

By End User:

• Academic Institutes and Research Centers
• Life Sciences Companies
• Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs)

By Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Gene Editing Technologies Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01122025004107003653ID1110419950